Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel: +47 21 07 81 60
E-mail:

Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2026 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2026.

ATC code	ATC level name (INN/generic name)	DDD	Unit	Adm.route

A07AA13	rifamycin	0.8 ¹⁾	g	O
A10BH08	teneligliptin	20	mg	O
B06AX04	mitapivat	0.1	g	O
C03DA05	finerenone	20	mg	O
G04BD15	vibegron	75	mg	O
H02CA02	osilodrostat	10	mg	O
H05BX06	evocalcet	2.5	mg	O
J01AA13	eravacycline	0.14	g	P
J01DC52	cefuroxime and beta-lactamase inhibitor	0.5 ²⁾	g	O
J01DI04	cefiderocol	6	g	P
J02AA01	amphotericin B ³⁾	210	mg	P
J02AC06	oteseconazole	21	mg	O
J04AK08	pretomanid	0.2	g	O
J05AE16	ensitrelvir	0.175	g	O
J05AH04	laninamivir	0.16	g	Inhal.solution
J05AP13	ravidasvir	0.2	g	O
J05AX10	maribavir	0.8	g	O
J05AX24	tecovirimat	1.2	g	O
J05AX28	bulevirtide	2	mg	P
J05AX31	lenacapavir	0.19	g	O
J05AX31	lenacapavir	5.1	mg	P
L01EA06	asciminib	80	mg	O
L01EL04	orelabrutinib	0.15	g	O
L01EX21	tepotinib	0.45	g	O
L04AA03	antilymphocyte immunoglobulin (horse)	1.05	g	P
L04AC19	satralizumab	4.3	mg	P
L04AC22	spesolimab	0.9 ⁴⁾	g	P
L04AD03	voclosporin	47.4	mg	O
L04AG11	anifrolumab	10.7	mg	P
L04AJ03	pegcetacoplan	0.3	g	P
N02CC08	lasmiditan	0.1	g	O
N02CD05	eptinezumab	1.1	mg	P
R05DB29	gefapixant	90	mg	O
V03AX04	difelikefalin	15	mcg	P

1) as sodium salt
2) refers to cefuroxime
3) lipid formulations
4) course dose

Last updated: 2026-01-22